A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MTRX1011A in Patients With Rheumatoid Arthritis

Summary

This is a Phase I multicenter study that will be conducted in the United States and consists of a double-blind, placebo-controlled, SAD stage, followed by a double-blind, placebo controlled MAD stage. The study will be conducted in approximately 65 adult patients between 18 and 80 years old who have RA.

Timeline

Start

2008-07

Primary completion

2009-12

Completion

—

Outcome

Outcome not reported

Stopped (Enrollment): “Study had completed enrollment but drug injection was halted due to an unacceptable incidence of rash.”

Drugs

Indications